Boston Partners
AXDX

Boston Partners’s Accelerate Diagnostics AXDX Stock Holding History

Boston Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,700
Closed -$300K – 694
2013
Q2 		$300K Buy
+3,700
New +$275K ﹤0.01% 677

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's AXDX Position: Q3 2013 in Review

Boston Partners sold out of Accelerate Diagnostics (AXDX) in Q3 2013, closing a stake of 3,700 shares — an estimated $300K sold.

Boston Partners first reported a position in AXDX in Q2 2013 and held it in 1 quarter. The position peaked at $300K in Q2 2013. 47 funds tracked by Wall St. Rank hold AXDX as of Q3 2013.

  • Boston Partners reported no remaining Accelerate Diagnostics position as of Q3 2013 after selling out during the quarter.
  • Boston Partners sold 3,700 Accelerate Diagnostics shares in Q3 2013, an estimated $300K.
  • Boston Partners first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 1 quarter.
  • Boston Partners's Accelerate Diagnostics position peaked at $300K in Q2 2013.
  • 47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2013.

Based on Boston Partners's 13F filing for Q3 2013, filed 12 Nov 2013.